Status: Ongoing First registered on: 28/03/2019
Last updated on: 02/09/2019
1. Study identification
EU PAS Register NumberEUPAS29076
Official titleQuality of asthma treatment in children and adolescents
Study title acronymQUAST
Study typeObservational study
Brief description of the studyAsthma is the most common chronic child and adolescent disease with a prevalence that has increased significantly over the past 20 years worldwide as well as the use of antiasthmatic medications. Little is known about the short and long-term therapeutic management of asthmatic children. Pharmacological treatment aims durable asthma control but despite the existence of international recommendations for the proper use of anti-asthma drugs and inhalation medical devices in this population, asthma control remains unacceptable for at least one-third of asthmatic children and adolescents. The aim of this study is to assess the prescribing patterns of antiasthma drugs and inhalation medical devices, oral corticosteroids and antibiotics in asthmatic children in primary care in France in order to identify deviations from recommendations.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)? Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsParis Pharmacoepidemiology Centre
Department/Research groupCentre de pharmaco-épidémiologie
Organisation/affiliationAssistance Publique - Hôpitaux de Paris
Website/Homepage
Details of (Primary) lead investigator
Title Dr
Last name KAGUELIDOU
First name Florentia
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)

Countries in which this study is being conducted
National study

France
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed02/11/2016
Start date of data collection01/01/201811/05/2018
Start date of data analysis
Date of interim report, if expected
Date of final study report31/12/2020
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government bodyANSM100
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name KAGUELIDOU
First name Florentia
Address line 1Robert Debré Hospital, Clinical Investigations Center, inserm CIC1426, 48 boulevard Sérurier
Address line 2 
Address line 3 
CityParis 
Postcode75019 
CountryFrance
Phone number (incl. country code)33140034142 
Alternative phone number 
Fax number (incl. country code) 
Email address florentia.kaguelidou@aphp.fr
Public Enquiries
Title Dr 
Last name KAGUELIDOU 
First name Florentia 
Address line 1Robert Debré Hospital, Clinical Investigations Center, inserm CIC1426, 48 boulevard Sérurier 
Address line 2 
Address line 3 
CityParis 
Postcode75019 
CountryFrance 
Phone number (incl. country code)33140034142 
Alternative phone number 
Fax number (incl. country code) 
Email address florentia.kaguelidou@aphp.fr 
Top